Guidance, NICE advice and quality standards in development

Showing 41 to 50 of 340

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]	Technology appraisal guidance	20 February 2019
Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180]	Technology appraisal guidance	TBC
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]	Technology appraisal guidance	20 November 2024
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]	Technology appraisal guidance	TBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]	Technology appraisal guidance	13 November 2024
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]	Technology appraisal guidance	TBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]	Technology appraisal guidance	TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]	Technology appraisal guidance	13 November 2024
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]	Technology appraisal guidance	24 May 2019
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC